Chicago, July 04, 2022 (GLOBE NEWSWIRE) -- According to the new market research report “Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027”, published by MarketsandMarkets™, the global market is projected to reach USD 4.5 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 17.7 % during the forecast period of 2022 to 2027.
Browse in-depth TOC on “Stem Cell Assays Market”
393 – Tables
47 – Figures
331 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47610330
The stem cell assays market is expected to grow at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by increasing funding for stem cell research, rising demand for cell-based assays in drug discovery, and the rising incidence of cancer across the globe.
The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.
Cell viability assays help to determine the number of live and dead cells in a culture medium. The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays. The segment accounted for the largest share on 2021. Increase in demand for stem cell assays in drug discovery and development is projected to drive the segment growth.
The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021.
The adult stem cells accounted for the largest share of the stem cell assay market. The stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells. Increasing demand for mesenchymal stem cells and induced pluripotent stem cells for development of stem cell based therapies and rising R&D spending are various factors projected to drive the segment growth.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=47610330
The Asia Pacific region is the fastest-growing region of the stem cell assays market in 2021.
The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the stem cell assays markets of China and India is mostly driven by growing public-private funding to support stem cell product development and commercialization and rising prevalence of cancer & other diseases. Furthermore, growing emphasis on strategic initiatives (such as acquisitions, partnerships, and collaborations) by biopharma and biotech companies is expected to support the market growth in the region.
Key players in Stem Cell Assays Market include:
Thermo Fisher Scientific Inc. (US),
Merck KGaA (Germany),
Becton, Dickinson and Company (US),
Bio-Rad Laboratories (US),
Agilent Technologies (US),
Promega Corporation (US),
Cell Biolabs (US),
Miltenyi Biotec (Germany),
STEMCELL Technologies (Canada),
Bio-Techne Corporation (US),
FUJIFILM Holdings Corporation (Japan),
Charles River Laboratories (US),
HemoGenix Inc. (US),
Lonza Group (Switzerland),
Takara Bio Inc. (Japan),
Creative Bioarray (US),
AAT Bioquest, Inc. (US),
BPS Bioscience, Inc. (US),
Enzo Biochem (US),
PromoCell GmbH (Germany),
Geno Technology (US),
Abcam plc (UK), and
ReachBio Research Labs (US).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=47610330
Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting
Browse Related Reports:
Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) (2022 - 2026)
Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025
CONTACT: About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: email@example.com